These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20560287)

  • 41. [New therapeutic strategies in idiopathic pulmonary fibrosis].
    Ancochea J; Antón E; Casanova A
    Arch Bronconeumol; 2004 Dec; 40 Suppl 6():16-22. PubMed ID: 16137462
    [No Abstract]   [Full Text] [Related]  

  • 42. Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end.
    Wijsenbeek MS; Kool M; Cottin V
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30545962
    [No Abstract]   [Full Text] [Related]  

  • 43. Promising Idiopathic Pulmonary Fibrosis Therapeutics.
    O'Callaghan M; McCarthy C; Keane MP
    Ir Med J; 2022 Oct; 115(No.9):667. PubMed ID: 36920324
    [No Abstract]   [Full Text] [Related]  

  • 44. GPR84: an immune response dial?
    Wojciechowicz ML; Ma'ayan A
    Nat Rev Drug Discov; 2020 Jun; 19(6):374. PubMed ID: 32494048
    [No Abstract]   [Full Text] [Related]  

  • 45. What if we made stratified medicine work for patients?
    Britten N; Pope C; Halford S; Richeldi L
    Lancet Respir Med; 2016 Jan; 4(1):8-10. PubMed ID: 26762661
    [No Abstract]   [Full Text] [Related]  

  • 46. The battlefield of rare diseases: where uncommon insights are common.
    Gahl WA
    Sci Transl Med; 2012 Oct; 4(154):154ed7. PubMed ID: 23035044
    [No Abstract]   [Full Text] [Related]  

  • 47. Repositioning compounds for idiopathic pulmonary fibrosis treatment: seeking the future in the past.
    Crestani B
    Eur Respir J; 2024 May; 63(5):. PubMed ID: 38754951
    [No Abstract]   [Full Text] [Related]  

  • 48. The treatment paradox: Most get nothing.
    Samarkos M
    BMJ; 2008 Jan; 336(7637):174. PubMed ID: 18219014
    [No Abstract]   [Full Text] [Related]  

  • 49. Could a Nebulized or Dry Powder Inhalation of a Dopamine D1R Agonist Be a Treatment of Idiopathic Pulmonary Fibrosis?
    Andresen BT
    J Pharmacol Exp Ther; 2023 Sep; 386(3):274-276. PubMed ID: 37591657
    [No Abstract]   [Full Text] [Related]  

  • 50. Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
    Maher TM
    Ann Am Thorac Soc; 2021 Aug; 18(8):1285-1286. PubMed ID: 34328404
    [No Abstract]   [Full Text] [Related]  

  • 51. Quercetin in Idiopathic Pulmonary Fibrosis: Another Brick in the Senolytic Wall.
    Sellarés J; Rojas M
    Am J Respir Cell Mol Biol; 2019 Jan; 60(1):3-4. PubMed ID: 30211613
    [No Abstract]   [Full Text] [Related]  

  • 52. Identifying "Real" Patients in the Real World.
    Callahan SJ
    Am J Respir Crit Care Med; 2020 Jan; 201(2):256-257. PubMed ID: 31419386
    [No Abstract]   [Full Text] [Related]  

  • 53. Reply to Callahan: Identifying "Real" Patients in the Real World.
    Dempsey TM; Limper AH
    Am J Respir Crit Care Med; 2020 Jan; 201(2):257-258. PubMed ID: 31419393
    [No Abstract]   [Full Text] [Related]  

  • 54. Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis.
    Kou L; Kou P; Luo G; Wei S
    Oxid Med Cell Longev; 2022; 2022():6197219. PubMed ID: 35345828
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The quest for the initial lesion in idiopathic pulmonary fibrosis: gene expression differences in IPF fibroblasts.
    Eickelberg O; Laurent GJ
    Am J Respir Cell Mol Biol; 2010 Jan; 42(1):1-2. PubMed ID: 20026648
    [No Abstract]   [Full Text] [Related]  

  • 56. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis.
    Williamson JD; Sadofsky LR; Hart SP
    Exp Lung Res; 2015 Mar; 41(2):57-73. PubMed ID: 25514507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model.
    Jarman ER; Khambata VS; Cope C; Jones P; Roger J; Ye LY; Duggan N; Head D; Pearce A; Press NJ; Bellenie B; Sohal B; Jarai G
    Am J Respir Cell Mol Biol; 2014 Jan; 50(1):158-69. PubMed ID: 23977848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The definition of fibrogenic processes in fibroblastic foci of idiopathic pulmonary fibrosis based on morphometric quantification of extracellular matrices.
    Yamashita M; Yamauchi K; Chiba R; Iwama N; Date F; Shibata N; Kumagai H; Risteli J; Sato S; Takahashi T; Ono M
    Hum Pathol; 2009 Sep; 40(9):1278-87. PubMed ID: 19386353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antioxidant therapy for idiopathic pulmonary fibrosis. A promising therapeutic prospect.
    Tomioka H
    Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(2):83-4. PubMed ID: 20560287
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.